Toggle light / dark theme

CLEVELAND, Ohio — The Cleveland Clinic and IBM have entered a 10-year partnership that will install a quantum computer — which can handle large amounts of data at lightning speeds — at the Clinic next year to speed up medical innovations.

The Discovery Accelerator, a joint Clinic-IBM center, will feature artificial intelligence, hybrid cloud data storage and quantum computing technologies. A hybrid cloud is a data storage technology that allows for faster storage and analysis of large amounts of data.

The partnership will allow Clinic researchers to use the advanced tech in its new Global Center for Pathogen Research and Human Health for research into genomics, population health, clinical applications, and chemical and drug discovery.

Distribution bots.


Boston Dynamics is best known for its robot dog Spot, a machine designed to work in a range of environments, from offshore oil rigs to deep underground mines. But in recent years, the company has increasingly focused attention on the logistics space, and today is unveiling a new robot with just one application in mind: moving boxes in warehouses.

The robot is called Stretch and looks relatively dull for a Boston Dynamics creation. It’s not modeled after humans or animals, and instead aims to be as practical as possible. It has a square mobile base containing a set of wheels, a “perception mast” with cameras and other sensors, and a huge robotic arm with seven degrees of freedom and a suction pad array on the end that can grab and move boxes up to 23 kilograms (50 lbs) in weight.

What connects Stretch to other Boston Dynamics machines is a focus on mobility. Usually, when automation equipment is installed in warehouses the system is bolted down in one place with a workflow modeled around it. Stretch, by comparison, is designed to slide into any existing workplace where it could be useful loading or unloading goods.

You are constantly adjusting your walking parameters based on the feedback you’re getting from your environment. You walk differently on a soft surface, you prepare yourself before using stairs. Meanwhile robots cannot really do that, especially exoskeletons. These robotic legs could help disabled people walk again on their own, but how could they prepare to stop, climb stairs, make a sharp turn? Scientists believe that in the future exoskeletons are going to be smart thanks to cameras and artificial intelligence.

Currently exoskeletons need to be controlled manually via smartphone applications or joysticks. This is less than ideal, because the disabled person can’t walk as intuitively as an able-bodied person can. And his or her hands are always occupied with these controls. That kind of a cognitive load is extremely tiring and can be dangerous over time. Could you imagine needing to take out your phone every time you want to climb a set of stairs or walk through a strip of sand? Scientists want to borrow a page from a book about autonomous cars and therefore are optimizing AI computer software to process the video feed to accurately recognize stairs, doors and other features of the surrounding environment.

Brokoslaw Laschowski, leader of the ExoNet research project, said: “Our control approach wouldn’t necessarily require human thought. Similar to autonomous cars that drive themselves, we’re designing autonomous exoskeletons that walk for themselves.”

Cellular senescence is a hallmark of aging, whose onset is linked to a series of both cell and non-cell autonomous processes, leading to several consequences for the organism. To date, several senescence routes have been identified, which play a fundamental role in development, tumor suppression and aging, among other processes. The positive and/or negative effects of senescent cells are directly related to the time that they remain in the organism. Short-term (acute) senescent cells are associated with positive effects; once they have executed their actions, immune cells are recruited to remove them. In contrast, long-term (chronic) senescent cells are associated with disease; they secrete pro-inflammatory and pro-tumorigenic factors in a state known as senescence-associated secretory phenotype (SASP). In recent years, cellular senescence has become the center of attention for the treatment of aging-related diseases. Current therapies are focused on elimination of senescent cell functions in three main ways: i) use of senolytics; ii) inhibition of SASP; and iii) improvement of immune system functions against senescent cells (immunosurveillance). In addition, some anti-cancer therapies are based on the induction of senescence in tumor cells. However, these senescent-like cancer cells must be subsequently cleared to avoid a chronic pro-tumorigenic state. Here is a summary of different scenarios, depending on the therapy used, with a discussion of the pros and cons of each scenario.

Keywords: cellular senescence, senolytics, senomorphics, immunosurveillance, anti-aging therapies.

Cellular senescence is a stress response mechanism induced by different types of insults such as telomere attrition, DNA damage, and oncogenic mutations, among others [1]. First described in cultured human diploid fibroblasts after successive rounds of division [2], its main hallmarks are irreversible growth arrest, alterations of cell size and morphology, increased lysosomal activity, expression of anti-proliferative proteins, resistance to apoptosis, activation of damage-sensing signaling routes. Another important characteristic is the regulated secretion of interleukins (ILs), inflammatory factors, chemokines, proteases and growth factors, termed the senescence-associated secretory phenotype (SASP) [3].

Doctors take a microscopic craft loaded with cancer-killing chemicals, inject it into the human body, and drive it to a malignant tumor to deliver its payload before making a quick exit. The plan is to move to clinical trials by 2023.


Chemotherapy and radiation can cause too much collateral damage to treat some brain tumors. Crumb-sized robots could be the solution.